Peter S Ostling1, Kelly S Davidson1, Best O Anyama1, Erik M Helander1, Melville Q Wyche2, Alan D Kaye3,4. 1. Department of Anesthesiology, LSUHSC, 1542 Tulane Avenue, Suite 659, New Orleans, LA, 70112, USA. 2. Department of Pharmacology, LSUHSC, New Orleans, LA, USA. 3. Department of Anesthesiology, LSUHSC, 1542 Tulane Avenue, Suite 659, New Orleans, LA, 70112, USA. akaye@lsuhsc.edu. 4. Department of Pharmacology, LSUHSC, New Orleans, LA, USA. akaye@lsuhsc.edu.
Abstract
PURPOSE OF REVIEW: In the USA, there has been a sharp increase in heroin, prescription opiate, and illicitly manufactured fentanyl abuse with overdoses tripling since the 1990s. Several states have been deemed as "high-burden" abuse states where there is a greater proportion of synthetic opiate use. During the same period that prescription limitations were initially implemented throughout the country, the fentanyl epidemic started nationwide. RECENT FINDINGS: In the setting of data demonstrating an almost fourfold increase in overdose deaths from 1999 to 2008, states began restricting access to Food and Drug Agency (FDA) approved opioid medications. Another factor further exacerbating the opioid crises is that the cost of all formulations of naloxone has increased significantly over the past several years. In order to combat the opioid epidemic, stricter prescribing practices and prescription-monitoring programs have been instituted. Also, improvements in abuse-deterrent strategies for all opioid preparations can play an important role by increasing the safety of these medications and is a major focus of the FDA.
PURPOSE OF REVIEW: In the USA, there has been a sharp increase in heroin, prescription opiate, and illicitly manufactured fentanyl abuse with overdoses tripling since the 1990s. Several states have been deemed as "high-burden" abuse states where there is a greater proportion of synthetic opiate use. During the same period that prescription limitations were initially implemented throughout the country, the fentanyl epidemic started nationwide. RECENT FINDINGS: In the setting of data demonstrating an almost fourfold increase in overdose deaths from 1999 to 2008, states began restricting access to Food and Drug Agency (FDA) approved opioid medications. Another factor further exacerbating the opioid crises is that the cost of all formulations of naloxone has increased significantly over the past several years. In order to combat the opioid epidemic, stricter prescribing practices and prescription-monitoring programs have been instituted. Also, improvements in abuse-deterrent strategies for all opioid preparations can play an important role by increasing the safety of these medications and is a major focus of the FDA.
Authors: Bart J Morlion; Stefan A Mueller-Lissner; Renato Vellucci; Wojciech Leppert; Benoît C Coffin; Sara L Dickerson; Tony O'Brien Journal: Pain Pract Date: 2017-11-28 Impact factor: 3.183
Authors: Laxmaiah Manchikanti; Adam M Kaye; Nebojsa Nick Knezevic; Heath McAnally; Konstantin Slavin; Andrea M Trescot; Susan Blank; Vidyasagar Pampati; Salahadin Abdi; Jay S Grider; Alan D Kaye; Kavita N Manchikanti; Harold Cordner; Christopher G Gharibo; Michael E Harned; Sheri L Albers; Sairam Atluri; Steve M Aydin; Sanjay Bakshi; Robert L Barkin; Ramsin M Benyamin; Mark V Boswell; Ricardo M Buenaventura; Aaron K Calodney; David L Cedeno; Sukdeb Datta; Timothy R Deer; Bert Fellows; Vincent Galan; Vahid Grami; Hans Hansen; Standiford Helm Ii; Rafael Justiz; Dhanalakshmi Koyyalagunta; Yogesh Malla; Annu Navani; Kent H Nouri; Ramarao Pasupuleti; Nalini Sehgal; Sanford M Silverman; Thomas T Simopoulos; Vijay Singh; Daneshvari R Solanki; Peter S Staats; Ricardo Vallejo; Bradley W Wargo; Arthur Watanabe; Joshua A Hirsch Journal: Pain Physician Date: 2017-02 Impact factor: 4.965
Authors: Alan D Kaye; Mark R Jones; Adam M Kaye; Juan G Ripoll; Donald E Jones; Vincent Galan; Burton D Beakley; Frank Calixto; Jamie L Bolden; Richard D Urman; Laxmaiah Manchikanti Journal: Pain Physician Date: 2017-02 Impact factor: 4.965
Authors: Alan D Kaye; Mark R Jones; Adam M Kaye; Juan G Ripoll; Vincent Galan; Burton D Beakley; Frank Calixto; Jamie L Bolden; Richard D Urman; Laxmaiah Manchikanti Journal: Pain Physician Date: 2017-02 Impact factor: 4.965
Authors: Alexis B Peterson; R Matthew Gladden; Chris Delcher; Erica Spies; Amanda Garcia-Williams; Yanning Wang; John Halpin; Jon Zibbell; Carolyn Lullo McCarty; Jolene DeFiore-Hyrmer; Mary DiOrio; Bruce A Goldberger Journal: MMWR Morb Mortal Wkly Rep Date: 2016-08-26 Impact factor: 17.586
Authors: Collin Clarke; Andrew McClure; Laura Allen; Luke Hartford; Julie Ann Van Koughnett; Daryl Gray; Patrick B Murphy; Chris Vinden; Ken Leslie; Kelly N Vogt Journal: Br J Pain Date: 2021-08-13
Authors: Anika M Toorie; Fair M Vassoler; Fangfang Qu; Christopher M Schonhoff; Steven Bradburn; Christopher A Murgatroyd; Donna K Slonim; Elizabeth M Byrnes Journal: Addict Biol Date: 2019-11-28 Impact factor: 4.280
Authors: Guilherme S Lopes; Suzette Bielinski; Ann M Moyer; Debra J Jacobson; Liwei Wang; Ruoxiang Jiang; Nicholas B Larson; Virginia M Miller; Ye Zhu; Dana C Cavanaugh; Jennifer St Sauver Journal: BMJ Open Date: 2021-06-30 Impact factor: 3.006
Authors: Gregory Glauser; Zarina S Ali; Diana Gardiner; Ashwin G Ramayya; Rachel Pessoa; M Sean Grady; William C Welch; Eric L Zager; Esther Sim; Virginia Haughey; Brian Wells; Michael Restuccia; Gordon Tait; Glenn Fala; Neil R Malhotra Journal: Mhealth Date: 2019-09-24